Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 20, Issue 2, 2009, Pages

  Harris, Marianne ^a   Angel, Jonathan B ^b   Baril, Jean Guy ^c   Rachlis, Anita ^d   Trottier, Benoit ^e  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Etravirine; HIV; NNRTI; Recommendations; Resistance; TMC125; Treatment

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; CLARITHROMYCIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; ELVITEGRAVIR; ENFUVIRTIDE; ETHINYLESTRADIOL; ETRAVIRINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; METHADONE; NORETHISTERONE; OMEPRAZOLE; RALTEGRAVIR; RANITIDINE; RIFABUTIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; SILDENAFIL; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANXIETY DISORDER; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; PANCREATITIS; PHYSICIAN; PRACTICE GUIDELINE; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; VIRUS LOAD;

EID: 67049099295     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2009/658125     Document Type: Review

References (91)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, 2008;1-134. 〈http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf〉 (Version current at March 1, 2009).
2. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society - USA panel. JAMA 2008;300:555-570
3. Harris M, Montaner JSG. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol 2000;10:217-229 (Pubitemid 30465987)
4. Gazzard BG; the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. 〈http://www.bhiva.org/files/file1030835. pdf〉 (Version current at March 1, 2009).
5. Viramune package insert. Boehringer Ingelheim, 2007.
6. Sustiva package insert. Bristol-Myers Squibb, 2007.
7. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study. J Acquir Immune Defic Syndr 2004;35:492-502. (Pubitemid 38420658)
8. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125
9. Antinori A, Zaccarelli M, Cingolani A, et al. Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:835-838 (Pubitemid 35034664)
10. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38:37-42. (Pubitemid 40094116)
11. Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178 (Pubitemid 46541620)
12. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients in the randomized evaluation of strategic intervention in multi-drug resistant patients with tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475 (Pubitemid 44142769)
13. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185 (Pubitemid 36618128)
14. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195 (Pubitemid 36618129)
15. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc in antiretroviral-experienced patients infected with CCR5-tropic HIV-1: 48-week results of MOTIVATE 1. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2007. (Abst)
16. Fatkenheuer G, Konourina I, Nelson M, et al. Efficacy and safety of maraviroc (MVC) plus optimized background therapy (OBT) in viraemic, antiretroviral treatment-experienced patients infected with CCR5-tropic (R5) HIV-1 in Europe, Australia, and North America (MOTIVATE 2): 48-week results. The 11th European AIDS Conference. Madrid, October 24 to 27, 2007. (Abst)
17. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007;369:1261-1269 (Pubitemid 46553846)
18. US Food and Drug Administration, Center for Drug Evaluation and Research Alert. Darunavir ethalolate (marketed as Prezista) information. 〈http://www.fda.gov/cder/drug/infopage/darunavir/default.htm〉 (Version current at March 1, 2009).
19. Shidhaye SS, Hemant P, Majid H, Kadam V. HIV management: New approaches. Curr Drug Ther 2007;2:111-119 (Pubitemid 46812951)
20. Aptivus package insert. Boehringer Ingelheim, 2007.
21. Prezista package insert. Ortho Biotech Products, LP, 2007.
22. Whitcomb JM, Huang W, Fransen S, et al. Analysis of baseline enfuvirtide (T20) susceptibility and co-receptor tropism in two-phase III study populations. The 10th Conference on Retroviruses and Opportunistic Infections. Boston, February 10 to 14, 2003. (Abst)
23. Paxinos EE, Fransen S, Huang W, et al. Measuring HIV-1 co-receptor tropism using a recombinant virus assay. The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27 to 30, 2002. (Abst)
24. Trottier B, Walmsley S, Reynes J, et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-421 (Pubitemid 41669174)
25. Melby T, DeSpirito M, DeMasi R, et al. HIV-1 coreceptor use in triple-class treatment-experienced patients: Baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis 2006;194:238-246 (Pubitemid 44087196)
26. Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007;44:591-595 (Pubitemid 46233265)
27. Haslinger BA, Arendt G. TMC-125. Curr Opin Inv Drugs 2004;5:208-213
28. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-2560 (Pubitemid 38580092)
29. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005;79:12773-12782 (Pubitemid 41433197)
30. Figueiredo A, Moore KL, Mak J, et al. Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog 2006;2:e119. (Pubitemid 44818625)
31. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125 - a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 2003;17:49-54. (Pubitemid 38402332)
32. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-4686 (Pubitemid 39577672)
33. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38. (Pubitemid 47017466)
34. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48. (Pubitemid 47017467)
35. Haubrich R, Cahn P, Grinsztejn B, et al. DUET-1: Week 48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 612 treatment-experienced HIV-1-infected patients. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
36. Johnson M, Campbell T, Clotet B, et al. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
37. The TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. AIDS 2007;21:F1-F10.
38. Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetics and pharmacodynamics of TMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Los Angeles, February 25 to 28, 2007. (Abst)
39. Cohen C, Steinhart C, Ward D, et al. Efficacy and safety results at 48 weeks with the novel NNRTI, TMC125, and impact of baseline resistance on the virologic response in study TMC125-C223. XVI International AIDS Conference. Toronto, August 13 to 18, 2006. (Abst)
40. Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in Study TMC125-C227. The 8th International Congress on Drug Therapy in HIV Infection. Glasgow, November 12 to 16, 2006. (Abst)
41. Scholler M, Hoetelmans R, Beets G, et al. Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24 to 27, 2005. (Abst)
42. Gatell J, Beatty G, Johnson M, et al. Impact of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining illnesses and deaths): 24-week findings from a planned pooled analysis of the DUET studies. The 11th European AIDS Conference. Madrid, October 24 to 27, 2007. (Abst)
43. Peeters K, Viala M, Gilet H, et al. Health-related quality of life (HRQL) as measured by the Functional Assessment of HIV Infection (FAHI) questionnaire in treatment-experienced HIV-1-infected patients: 24-week results from the pooled DUET trials. The 11th European AIDS Conference. Madrid, October 24 to 27, 2007. (Abst)
44. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naïve, HIV-1 infected patients. AIDS 2003;17:2487-2494 (Pubitemid 38393321)
45. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in once- and twice-daily regimens in HIV-1-negative volunteers. Tthe 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2007. (Abst)
46. Kakuda TN, Konigs C, Feiterna-Sperling C, et al. Pharmacokinetics of the next-generation NNRTI etravirine (ETR; TMC125) in HIV-infected children between 6 and 17 years, inclusive. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
47. Montaner J, Domingo P, Junod P, et al. Safety and tolerability of TMC125 in 3-class-experienced HIV-infected patients: 24-week primary analysis of trial TMC125-C203. 10th European AIDS Conference. Dublin, October 17 to 20, 2005. (Abst)
48. Haubrich R, Schechter M, Walmsley S, et al. TMC125 safety and tolerability: 24-week results of the pooled DUET-1 and -2 trials. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2007. (Abst)
49. Intelence (etravirine; TMC125) package insert. Tibotec Inc, 2008.
50. Campbell T, Mills A, Morlat P, Schechter M, et al. TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUET-2. HEP DART: Frontiers in Drug Development for Antiretroviral Therapies. Hawaii, December 9 to 13, 2007. (Abst)
51. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649
52. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetics of TMC125 in HIV-1-negative volunteers with mild or moderate hepatic impairment. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2007. (Abst)
53. Woodfall B, Peeters M, Vingerhoets J, et al. The role of NNRTIs in treatment experienced patients - an update on TMC125. HIV DART. Cancun, December 10 to 14, 2006. (Abst)
54. Di Perri G, Girard PM, Clumeck N, et al. Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety and tolerability in treatment-experienced, HIV-1-infected patients. The 11th European AIDS Conference. Madrid, October 24 to 27, 2007. (Poster P7.3/12).
55. Hicks C, Cahn P, Leider J, et al. Pooled 24-week results of DUET-1 and -2: Efficacy of TMC125 in treatment-experienced HIV-1-infected patients. The 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, October 4 to 7, 2007. (Abst)
56. Grossman HA, Hicks C, Shalit P, et al. Efficacy and tolerability of TMC125 in HIV patients with NNRTI and PI resistance at 24 weeks: TMC125-C223. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, December 16 to 19, 2005. (Abst)
57. van der Ryst E, Cooper D, Konourina I, et al. Efficacy of maraviroc in combination with at least one other potent new antiretroviral drug: 24-week combined analysis of the MOTIVATE 1 and 2 studies. The 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, July 22 to 25, 2007. (Abst)
58. Cooper DA, Gatell J, Rockstroh, et al. 48-week results from BENCHMRK-1, a phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
59. Steigbigel R, Kumar P, Eron J, et al. 48-week results from BENCHMRK-2, a Phase III study of raltegravir (RAL) in patients failing antiretroviral therapy (ART) with triple-class resistant HIV-1. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
60. Virco Lab Inc. Clinical cut-offs. 〈http://www.vircolab.com/ bgdisplay.jhtml?itemname=vircotype-ccoffs&product=vircotype〉 (Version current at March 3, 2009).
61. Vingerhoets J, Clotet B, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials. The 11th European AIDS Conference. Madrid, October 24 to 27, 2007. (Abst)
62. Vingerhoets J, Buelens A, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 in the phase III clinical trials DUET-1 and DUET-2. The XVI International HIV Drug Resistance Workshop. Barbados, June 12 to 16, 2007. (Abst)
63. Picchio G, Vingerhoets J, Staes M, et al. Prevalence of etravirine (ETR; TMC125) resistance-associated mutations in a large panel of clinical isolates. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 5, 2008. (Abst)
64. Llibre JM, Santos JR, Pulg T, et al. Prevalence of mutations with impact on virological response to etravirine in routine clinical samples. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
65. Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007;60:1409-1410 (Pubitemid 350168348)
66. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Evaluating the role of etravirine in the second-line ART after failing an initial NNRTI-based regimen in a resource-limited setting. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
67. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): Multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. The XVIth International Drug Resistance Workshops. Sitges, June 10 to 14, 2008. (Abst)
68. Winters B, Vingerhoets J, Peeters M, et al. Development of vircoTYPE HIV-1 resistance analysis, including clinical cutoffs for TMC125, a new NNRTI. The 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 3 to 6, 2008. (Abst)
69. Boffito M, Winston A, Jackson A, et al. Pharmacokinetics and antiretroviral response to darunavir-ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007;21:1449-1455 (Pubitemid 46988005)
70. Montaner J, Harris M, Larsen G, et al. Combination of TMC114/ritonavir and TMC125 in patients with multidrug resistant HIV. XVI International AIDS Conference. Toronto, August 13 to 18, 2006. (Abst)
71. Kakuda TN, Scholler-Gyure M, Peeters M, et al. Pharmacokinetic interaction study with TMC125 and TMC114/r in HIV-negative volunteers. The XVI International AIDS Conference. Toronto, August 13 to 18, 2006. (Abst)
72. Piscitelli S, Baede P, Van 't Klooster G, Graham N. TMC125, a potent next generation NNRTI, does not alter lopinavir/ritonavir pharmacokinetics in healthy volunteers. The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 27 to 30, 2002. (Abst)
73. Harris M, Zala C, Ramirez S, et al. Pharmacokinetics (PK) and safety of adding TMC125 to stable regimens of saquinavir (SQV), lopinavir (LPV), ritonavir (RTV) and NRTIs in HIV+ adults. The 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5 to 9, 2006. (Abst)
74. Baede P, Piscatelli S, Graham N, van 't Klooster G. Drug interactions with TMC125, a potent next generation non-nucleoside reverse transcriptase inhibitor. The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 27 to 30, 2002. (Abst)
75. Anderson MS, Kakuda TN, Miller JL, et al. Pharmacokinetic evaluation of non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 and integrase inhibitor (InSTI) raltegravir (RAL) in healthy patients. The 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Sydney, July 22 to 25, 2007. (Abst)
76. Di Biagio A, Bruzzone B, Rosso, R, et al. Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS 2008;22:355-357 (Pubitemid 351735877)
77. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state pharmacokinetics of oral maraviroc in healthy patients. The 11th European AIDS Conference / (EACS). Madrid, October 24 to 27, 2007. (Abst)
78. Ramanathan S, West S, Kakuda TN, et al. Lack of clinically relevant drug interactions between ritonavir-boosted elvitegravir and TMC125. The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, September 17 to 20, 2007. (Abst)
79. Scholler M, Hoetelmans R, Bollen S, et al. No significant interaction between TMC125 and didanosine (ddI) in healthy volunteers. The 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 24 to 27, 2005. (Abst)
80. Scholler M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy patients. The 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5 to 9, 2006. (Abst)
81. Scholler-Gyure M, Woodfall B, Bollen S, et al. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir. The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 27 to 30, 2006. (Abst)
82. Scholler-Gyure M, Debroye C, Woodfall B, et al. Pharmacokinetic evaluation of the interaction between TMC125 and tenofovir disoproxil fumarate. The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September 27 to 30, 2006. (Abst)
83. Scholler-Gyure M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. The 8th International Congress on Drug Therapy in HIV Infection. Glasgow, November 12 to 16, 2006. (Abst)
84. Scholler-Gyure M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy patients. The 13th Conference on Retroviruses and Opportunistic Infections. Denver, February 5, 2006. (Abst)
85. Scholler-Gyure M, Debroye C, Vyncke V, et al. Effect of TMC125 on sildenafil pharmacokinetics. The 7th International Workshop of Clinical Pharmacology. Lisbon, April 20 to 22, 2006. (Abst)
86. Scholler-Gyure M, Woodfall B, Debroye C, et al. Pharmacokinetic interaction between TMC125 and rifabutin. The 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, October 12 to 15, 2006. (Abst)
87. Scholler-Gyure M, Debroye C, Woodfall B, et al. Pharmacokinetic interaction between TMC125 and clarithromycin. The 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, October 12 to 15, 2006. (Abst)
88. Scholler-Gyure M, Debroye C, Aharchi F, et al. No clinically relevant effect of TMC125 on the pharmacokinetics of oral contraceptives. The 8th International Congress on Drug Therapy in HIV Infection. Glasgow, November 12 to 16, 2006. (Abst)
89. Scholler-Gyure M, De Smedt G, Vanaken H, et al. TMC125 bioavailability is not affected by ranitidine and omeprazole. The XVI International AIDS Conference. Toronto, August 13 to 18, 2006. (Abst)
90. Scholler-Gyure M, Kakuda TN, De Smedt G, et al. Pharmacokinetic interaction between the non-nucleoside reverse transcriptase inhibitors (NNRTI) TMC125 and atorvastatin in HIV-negative volunteers. The 4th IAS Conference on HIV Pathogenesis. Sydney, July 22 to 25, 2007. (Abst)
91. Scholler-Gyure M, van den Brink W, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharm 2008;48:322-329 (Pubitemid 351257768)